<SEC-DOCUMENT>0001062993-24-015606.txt : 20240823
<SEC-HEADER>0001062993-24-015606.hdr.sgml : 20240823
<ACCEPTANCE-DATETIME>20240823162719
ACCESSION NUMBER:		0001062993-24-015606
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240822
FILED AS OF DATE:		20240823
DATE AS OF CHANGE:		20240823

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Taylor Stacy L
		CENTRAL INDEX KEY:			0001799081
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		241236642

	MAIL ADDRESS:	
		STREET 1:		C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
		STREET 2:		1551 EASTLAKE AVENUE E SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-08-22</periodOfReport>

    <issuer>
        <issuerCik>0001478320</issuerCik>
        <issuerName>Adaptive Biotechnologies Corp</issuerName>
        <issuerTradingSymbol>ADPT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001799081</rptOwnerCik>
            <rptOwnerName>Taylor Stacy L</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>1165 EASTLAKE AVENUE EAST</rptOwnerStreet2>
            <rptOwnerCity>SEATTLE</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98109</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>SVP and General Counsel</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-08-22</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>26922</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.4974</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>139365</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2024.</footnote>
        <footnote id="F2">The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $4.415 to $4.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Stacy L Taylor</signatureName>
        <signatureDate>2024-08-23</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
